Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M360Revenue (TTM) $M31.3Net Margin (%)-229.2Altman Z-Score3.6
Enterprise Value $M240EPS (TTM) $-2.4Operating Margin %-232.5Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-231.6Higher ROA y-yY
Price/Book2.910-y EBITDA Growth Rate %--Quick Ratio5.1Cash flow > EarningsY
Price/Sales9.15-y EBITDA Growth Rate %--Current Ratio5.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-45.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-60.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M37.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NLNK is held by these investors:



NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stine Seed Farm, Inc.10% Owner 2017-10-06Buy780,487$10.25-5.17view
Langren Carl W.Principal Accounting Officer 2016-12-14Sell3,943$10.85-10.41view
Talarico Ernest IIIDirector 2016-06-06Buy4,065$12.32-21.1view
Link Charles J. Jr.Chairman of the Board and CEO 2016-04-07Sell10,000$20.03-51.47view
Link Charles J. Jr.Chairman of the Board and CEO 2016-03-15Sell25,000$17.86-45.58view
Link Charles J. Jr.Chairman of the Board and CEO 2016-02-03Sell25,000$24.16-59.77view
HENNEMAN JOHN B IIIEVP, CFO 2016-01-05Sell175$35.74-72.8view
Wiley BrianVP of Business Development 2016-01-05Sell1,295$34.99-72.22view
Vahanian Nicholas N.President, Chief Medical Offic 2016-01-05Sell3,011$35.06-72.28view
Vahanian Nicholas N.President, Chief Medical Offic 2015-09-11Sell10,000$51.19-81.01view

Press Releases about NLNK :

Quarterly/Annual Reports about NLNK:

News about NLNK:

Articles On GuruFocus.com
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer Nov 14 2017 
NewLink Genetics to Participate in November Investor Conferences Nov 13 2017 
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program Nov 02 2017 
NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod  Oct 30 2017 
NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 201 Oct 20 2017 
NewLink Genetics Prices Public Offering of Common Stock Oct 03 2017 
NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Panc Sep 25 2017 
3 Stocks Soaring Today Sep 07 2017 
NewLink Genetics to Participate in Upcoming Investor Conferences Aug 29 2017 
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program Jul 28 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK